Orexigen® Therapeutics and Takeda Enter Into Partnership to Commercialize Contrave® in North America

2 September 2010, 3:43 am

SAN DIEGO and OSAKA, Japan, Sept. 2 /PRNewswire-FirstCall/ -- Orexigen® Therapeutics, Inc. (Nasdaq: OREX) and Takeda Pharmaceutical Company Limited (TSE: 4502), today announced that they have entered into an exclusive partnership to develop and commercialize Contrave® (naltrexone SR/bupropion SR), Orexigen's investigational drug for the treatment of obesity, in the United States, Canada and ...... Read More »

More Topics from "Articles"

• 2011 Award Recipients Named By Biophysical Society
• Abducted Japanese reporter returns home
• Japan's centenarians falling through the cracks
• Japan beat Paraguay to avenge WC defeat
• Ozawa says he stakes all on DPJ race
• Japan beat Paraguay to avenge World Cup defeat
• Japan PM leadership rival on the offensive
• Sharp Signs EUROTOP Sponsorship Agreement with UEFA
• For the latest news from Panasonic booth, please visit Cybershowcase Blog - http://ex-blog.panasonic.co ...